Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pharmaceutics ; 15(9)2023 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-37765180

RESUMEN

A solvate cocrystal of the antimicrobial norfloxacin (NFX) was formed by using isonicotinamide (INA) as a coformer with the solvent evaporation technique. The cocrystal formation was confirmed by performing solid-state characterization techniques. We evaluated the dissolution under supersaturated conditions and also the solubility at the vertex of triphasic domain of cocrystal and NFX in both water and Fasted-State Simulated Intestinal Fluid (FaSSIF). The antimicrobial activity was evaluated using the microdilution technique. The cocrystal showed 1.8 times higher dissolution than NFX in water at 60 min and 1.3 times higher in FaSSIF at 180 min in the kinetic study. The cocrystal also had an increase in solubility of 8.38 times in water and 6.41 times in FaSSIF. The biopharmaceutical properties of NFX with cocrystallization improved antimicrobial action, as shown in the results of minimum inhibitory concentration (MIC) and inhibitory concentrations of 50% (IC50%) and 90% (IC90%). This paper presents, for the first time, a more in-depth analysis of the cocrystal of NFX-INA concerning its dissolution, solubility, and antimicrobial activity. In all these criteria, the cocrystal obtained better results compared to the pure drug.

2.
J Control Release ; 350: 308-323, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35995298

RESUMEN

Oral sildenafil (SDF) is used to treat pulmonary arterial hypertension (PAH), and its bioavailability is approximately 40%. Several formulations of nano and microparticles (for pulmonary delivery) are being developed because it is possible to improve characteristics such as release time, bioavailability, dose, frequency, and even directly target the drug to the lungs. This review summarizes the latest SDF drug delivery systems for PAH and explains challenges related to the development, the preclinical, and the clinical studies. A scoping review was conducted by searching electronic databases including PubMed, Scopus, and Web of Science to identify studies published between 2001 and 2021. From 300 articles found, 31 met the inclusion criteria. This review identified colloidal formulations such as polymeric, lipid, and metal-organic framework nanoparticles. Strategies were determined to reach the deep airways such as polymeric microparticles, large porous microparticles, nanocomposites, and nano in microparticles. Finally, aspects related to toxicological, pharmacokinetics, and gaps in information for potential use in humans were discussed. SDF formulations are significant candidates for the treatment of PAH by inhalation. In summation, future preclinical studies are still required in large animals, as there is no particular formulation yet submitted to clinical studies.


Asunto(s)
Estructuras Metalorgánicas , Hipertensión Arterial Pulmonar , Administración por Inhalación , Animales , Hipertensión Pulmonar Primaria Familiar , Humanos , Lípidos , Pulmón , Nanotecnología , Citrato de Sildenafil
3.
Int J Biol Macromol ; 181: 697-704, 2021 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-33766602

RESUMEN

Starch nanoparticles (SNPs) have been applied to different areas of material sciences, especially in pharmaceuticals due to their characteristics such as small particle size, high surface ratio-volume, and biological compatibility. However, in pharmaceutical sciences, there are no records of a scoping review that had extensively mapped all available information about SNPs. A scoping review was performed here by searching electronic databases (Pubmed and Science Direct) to identify studies published previous to June 2020. From 699 total records, 37 matched the criteria for inclusion. The findings showed that SNPs have been used, not only for the development of different active pharmaceutical ingredient delivery systems, but also as an enzyme inhibitor, adsorption, and DNA precipitation agent. In conclusion, by combining different starch sources and methods SNPs show a remarkable diversity in pharmaceutical applications. Future studies should explore SNPs safety and provide information about variables that may affect important properties for this kind of application.


Asunto(s)
Nanopartículas/química , Preparaciones Farmacéuticas/química , Almidón/farmacología , Portadores de Fármacos/química , Publicaciones
4.
J Microbiol Methods ; 162: 50-61, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31078627

RESUMEN

The emergence of multiresistant bacteria directly impacts on the search for new compounds with antimicrobial activity, and it is important the improvement of new techniques are able to determine the minimum inhibitory concentration (MIC) of antimicrobial compounds. The microdilution technique is widely used for saving culture media, reagents and compounds to be tested. However, the literature does not describe a colorimetric method capable of correlating absorbance with concentration of viable microorganisms (CFU mL-1). Therefore, the novelty of this work was the standardization and validation of a colorimetric and quantitative method capable of determining the MIC of several compounds with antimicrobial activity and the conversion of absorbance values to CFU mL-1. The conditions carried out for the method were: the use of 0.125% (w/v) 2,3,5-triphenyltetrazolium chloride (TTC) solution added after 22 h of incubation at 35 °C, followed by 2 more hours of incubation and subsequent reading in a spectrophotometer. The tested microorganisms were: Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 8739), Pseudomonas aeruginosa (ATCC 9027) and Candida albicans (ATCC 10231). The method was validated and showed linearity (R2 > 0.95), precision (RSD <26%), accuracy (75% to 122%) and robustness (p > 0.05). The validated parameters ensured the harmonization of methodology to determine not only MIC as well as inhibitory concentrations of 50% (IC50%) and 90% (IC90%) of the antimicrobial compounds.


Asunto(s)
Candida albicans/efectos de los fármacos , Cloranfenicol/farmacología , Escherichia coli/efectos de los fármacos , Cetoconazol/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Staphylococcus aureus/efectos de los fármacos , Antibacterianos/farmacología , Colorimetría/métodos , Pruebas de Sensibilidad Microbiana
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA